Insider Trading April 21, 2026 06:28 PM

AEHR Test Systems EVP Vernon Rogers Sells $450,000 in Stock; Company Posts Record Order and Raises Capital

Executive sale coincides with a $60M at-the-market raise and a $41M production order tied to AI chip testing for data centers

By Marcus Reed AEHR
AEHR Test Systems EVP Vernon Rogers Sells $450,000 in Stock; Company Posts Record Order and Raises Capital
AEHR

Vernon Rogers, AEHR Test Systems' Executive Vice President of Sales & Marketing, sold 5,000 shares on April 20, 2026 for $90.00 apiece, totaling $450,000. Following the transaction he directly holds 147,716 shares, including unvested restricted stock units. The company recently completed a $60 million at-the-market offering and won a record $41 million production order from a hyperscale customer for AI chip testing equipment, with deliveries beginning in fiscal 2027. Analysts responded by raising price targets amid strong bookings and a modest revenue miss in Q3 FY26.

Key Points

  • EVP Vernon Rogers sold 5,000 AEHR shares on April 20, 2026, for $90.00 each, generating $450,000 in proceeds.
  • After the sale, Rogers directly holds 147,716 shares, a figure that includes unvested restricted stock units.
  • AEHR completed a $60 million at-the-market stock offering and secured a record $41 million production order from a hyperscale customer for AI chip testing equipment, with deliveries beginning in fiscal 2027.
  • Analysts increased price targets - Freedom Broker to $61 and Lake Street to $56 - citing strong bookings, despite a slight revenue miss in Q3 FY26.

Vernon Rogers, who serves as Executive Vice President of Sales & Marketing at AEHR Test Systems (NASDAQ:AEHR), executed an insider sale on April 20, 2026, disposing of 5,000 shares of the company's common stock at $90.00 per share. The trade produced gross proceeds of $450,000.

After the transaction, Mr. Rogers retains direct ownership of 147,716 AEHR common shares. That total includes shares that remain subject to unvested restricted stock units, as reported by the company.

Investors seeking additional analysis of AEHR’s valuation or operating performance can consult a comprehensive Pro Research Report that the company has made available for this and more than 1,400 other U.S. equities.


AEHR Test Systems has recently pursued multiple financing and commercial milestones. The company completed an at-the-market equity program that raised $60 million under an effective registration statement. That offering allowed AEHR to sell common stock into the market to raise capital.

Separately, AEHR reported securing a production order valued at $41 million from a hyperscale customer, the largest order in the company’s history. The order is for AI chip testing equipment, including high-power test systems designed to support AI workloads in data centers. AEHR expects deliveries on this production order to begin in fiscal 2027.


Market analysts adjusted their stances following these developments. Freedom Broker increased its price target on AEHR to $61, citing robust demand indicators despite a small revenue shortfall in the third quarter of fiscal 2026. AEHR reported $10.3 million in revenue for Q3 FY26, marginally under the $10.8 million consensus estimate, while achieving record bookings of $37.2 million for the period.

Lake Street also raised its price target, to $56, pointing to continued bookings momentum and a book-to-bill ratio above 3.5x. Both firms highlighted the strength of order intake as a central factor in their revised outlooks.


Taken together, the insider sale by Mr. Rogers, the $60 million at-the-market financing, and the record $41 million production order represent a cluster of corporate actions that investors and market observers will likely monitor closely. The production order ties AEHR directly to demand for AI-focused testing infrastructure in large-scale data center environments, while the equity offering provides additional liquidity to support the company’s operations and growth plans.

Risks

  • AEHR reported a slight revenue miss in Q3 FY26 - $10.3 million versus a $10.8 million consensus - which may signal short-term top-line pressure in the semiconductor test equipment market.
  • The $60 million at-the-market equity offering could result in share dilution for existing shareholders, depending on future issuances under the program.
  • The timing of expected deliveries for the $41 million production order begins in fiscal 2027, introducing execution and scheduling risk for revenue recognition tied to that order.

More from Insider Trading

CrowdStrike CEO George Kurtz Sells $2.13M in Stock Under Prearranged Plan Apr 21, 2026 Third Rock Ventures Sells $17.1M Stake in Rapport Therapeutics Apr 21, 2026 Astera Labs CEO Sells $57.85 Million in Stock; Holdings and Analyst Views Highlighted Apr 21, 2026 Aehr Test Systems Director Scott Gates Disposes $5.66 Million in Shares Apr 21, 2026 Arista Networks CTO Kenneth Duda Sells $9.47M in Stock as Shares Trade Near 52-Week High Apr 21, 2026